Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2024 EPS estimates for Atossa Therapeutics in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings of ($0.20) per share for the year, up from their prior estimate of ($0.22). The consensus estimate for Atossa Therapeutics' current full-year earnings is ($0.21) per share.
A number of other analysts have also issued reports on the company. StockNews.com lowered Atossa Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, November 8th. HC Wainwright increased their price target on Atossa Therapeutics from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, Ascendiant Capital Markets raised their price target on Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a research note on Wednesday, September 11th.
Read Our Latest Stock Analysis on Atossa Therapeutics
Atossa Therapeutics Stock Performance
Atossa Therapeutics stock remained flat at $1.28 during trading hours on Monday. 722,207 shares of the company's stock traded hands, compared to its average volume of 1,076,344. The company has a market cap of $161.03 million, a price-to-earnings ratio of -5.82 and a beta of 1.23. The business's 50-day simple moving average is $1.44 and its 200-day simple moving average is $1.37. Atossa Therapeutics has a 12 month low of $0.67 and a 12 month high of $2.31.
Institutional Investors Weigh In On Atossa Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in shares of Atossa Therapeutics by 3,160.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company's stock worth $490,000 after buying an additional 399,041 shares during the last quarter. Cetera Advisors LLC acquired a new position in Atossa Therapeutics during the 1st quarter valued at about $72,000. Virtu Financial LLC purchased a new stake in Atossa Therapeutics in the first quarter valued at about $151,000. Rhumbline Advisers acquired a new stake in Atossa Therapeutics in the second quarter worth about $161,000. Finally, Vanguard Group Inc. grew its stake in shares of Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company's stock worth $10,357,000 after acquiring an additional 78,269 shares during the last quarter. Institutional investors own 12.74% of the company's stock.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
See Also
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
